Orthoss
DeviceOrthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.
NCT Number: NCT03853356
This study aims to evaluate the performance and safety of the Orthoss® as a bone graft extender in lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1).
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Observational
Universitätsklinikum Augsburg - Neurochirurgische Klinik und Poliklinik, Augsburg, Germany
This clinical investigation is a prospective, non-interventional, uncontrolled clinical trial, organized to generate clinical data on performance and safety of Orthoss® as a bone graft extender mixed with local bone at ratio of 1:1 and pedicle bone marrow aspirate in lumbar spondylodesis involving 1-2 levels. (Orthoss® is CE marked for this indication).
If you as a patient have a wear and tear disease of the spine, an operation serves to restore the stability of the spinal column. In order to promote a bony build-up of the lumbar spine segment (fusion), bone replacement material is used in your case as standard. The aim of this observational study is to determine fusion in order to address clinical performance of that bone replacement material.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.
Time frame: 6 months
Successful fusion should be based on the translational motion < 3mm as well as on the angular motion < 5° at 6 months.
Time frame: 1-4 weeks; 3, 6, 12 and 24 months
Improvement in Oswestry Low Back Disability Index (ODI) of 15 or more at 24 months from the pre-operative value.Zero is equated with no disability and 100 is the maximum disability possible.
Time frame: 1-4 weeks, 3,6,12 and 24 months
Decrease in Visual Analog Scale for Pain (VAS) for leg by 3/10 or more at 24 months from the pre-operative value. Patients rated their leg pain intensity on a scale from 0-10, with a score of 0 representing "no pain" and a score fo 10 representing "pain as bad as it could be".
Time frame: 1-
Decrease in Visual Analog Scale for Pain (VAS) for back by 3/10 or more at 24 months from the pre-operative value. Patients rated their back pain intensity on a scale from 0-10, with a score of 0 representing "no pain" and a score fo 10 representing "pain as bad as it could be".
Geistlich Pharma AG
Industry
Acronym: EFFISO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07489001
Bone Diseases, Intervertebral Disc Degeneration
Istanbul, Maltepe, Turkey (Türkiye)
View Trial DetailsNCT04520334
Back Pain, Behavior
Dalby, Sweden
View Trial DetailsNCT04594980
Bone Diseases, Intervertebral Disc Degeneration
Moscow, Russia
View Trial DetailsNCT05029726
Bone Diseases, Cysts
Chicago, Illinois, United States
View Trial Details